This research appears in the print publication on the Internet of an advanced nature.
“This is a new type of treatment has the potential to help a large number of patients suffering from genetic diseases different to have the same type of mutation,” says senior author H. Lee Sweeney, Ph.D., Head of the Department of Physiology at the University of Pennsylvania.Famous Product Dr. Charles Livingston Fat Loss Factor
This genetic defect causes from 5 to 15 percent (and in some cases up to 70 percent) of individual cases of most inherited diseases, including DMD, cystic fibrosis, and hemophilia.
The new drug, developed by the South Plainfield, New Jersey Biotechnology Company, called PTC124, binds the ribosome, a cellular component where the genetic code is translated into proteins, one amino acid at a time. The drug allows the ribosome to read through an error in the genetic code called a stop codon is premature to make proteins correctly in full.
In the Doha Ministerial Declaration, and patients who are missing dystrophin, a protein that helps keep muscle cells intact.
About 15 percent of DMD patients do not make dystrophin because of the mutation. DMD eventually affects all voluntary muscles, as well as the muscles of the heart and breathing.